Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug;79(16):10103-7.
doi: 10.1128/JVI.79.16.10103-10107.2005.

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

John R Mascola  1 , Patricia D'Souza, Peter Gilbert, Beatrice H Hahn, Nancy L Haigwood, Lynn Morris, Christos J Petropoulos, Victoria R Polonis, Marcella Sarzotti, David C Montefiori
Affiliations

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

John R Mascola et al. J Virol. 2005 Aug.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Common types of assays used to measure neutralizing antibodies against HIV-1. Current assays differ with regard to the target cells used (e.g., neoplastic T-cell lines, primary human lymphocytes, or genetically engineered cell lines), the method used to measure infection (e.g., p24 antigen, reverse transcriptase, cell killing, plaque formation, or reporter gene expression), the type of virus used (e.g., uncloned PBMC-derived stocks, uncloned or molecularly cloned pseudoviruses, or replication-competent chimeric molecular clones), and whether single or multiple rounds of infection are permitted. Note that Env-pseudotyped viruses produce a single round of target cell infection. The plasmid expression vectors used to provide Env in trans can be clonal or can contain a quasispecies of env genes derived from a patient sample.
FIG. 2.
FIG. 2.
Multitier approach to assessing the neutralizing antibody response generated by candidate HIV-1 vaccines.
See this image and copyright information in PMC

References

    1. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunet, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Butron. 2004. Comprehensive cross-clade neutralization analysis of a panel of anit-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. - PMC - PubMed
    1. Brown, B. K., J. M. Darden, S. Tovanabutra, T. Oblander, J. Frost, E. Sanders-Buell, M. S. DeSouza, D. L. Birx, F. E. McCutchan, and V. R. Polonis. 2005. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79:6089-6101. - PMC - PubMed
    1. Derdeyn, C. A., J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, M. L. Heil, F. Kasolo, R. Musonda, B. H. Hahn, G. M. Shaw, B. T. Korber, S. Allen, and E. Hunter. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022. - PubMed
    1. Dorsky, D. I., M. Wells, and R. D. Harrington. 1996. Detection of HIV-1 infection with a green fluorescent protein reporter system. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:308-313. - PubMed
    1. Dreyer, K., E. G. Kallas, V. Planelles, D. Montefiori, M. P. McDermott, M. S. Hasan, and T. G. Evans. 1999. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 15:1563-1571. - PubMed

LinkOut - more resources